Patent intelligence · BR
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
Edição de gene para hemofilia a com expressão de fator viii melhorada
Patent details — BR 112021015776
- Jurisdiction
- BR
- Status
- granted
- Grant date
- Nov 9, 2021
- Expiration
- Nov 4, 2041
- Applicant
- BAYER HEALTHCARE LLC [US]
- CPC classes
- A61K 48/ 00 A I, A61K/4800, A61K/48005, A61K/480058
Quick answer
BR 112021015776 (Edição de gene para hemofilia a com expressão de fator viii melhorada) is held by BAYER HEALTHCARE LLC [US]. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER HEALTHCARE LLC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 48/ 00 A I, A61K/4800, A61K/48005, A61K/480058, A61K/480066, A61K/480075
More from BAYER HEALTHCARE LLC [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 112021015776?
BR 112021015776 (Edição de gene para hemofilia a com expressão de fator viii melhorada) is held by BAYER HEALTHCARE LLC [US]. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns BR 112021015776?
BAYER HEALTHCARE LLC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does BR 112021015776 expire?
Our index shows an expiration date of Nov 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.